drugset / Trial / NCT05889845

Candin for the Treatment of Common Warts

NCT05889845

Phase 3 Completed 330 enrolled Nielsen BioSciences, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to compare outcome in healthy subjects 12 years of age and older with at least 3, but no more than 20, common warts (Verruca vulgaris) following treatment with Candin or placebo. The main questions it aims to answer are: * does treatment with Candin result in better clearance of warts than placebo * how many injections are required to result in wart clearance Participants will * have one wart selected for injection every two weeks until clearance * return 12 weeks after wart clearance for assessment of durability of response

Timeline

Start
2025-01-22
Primary completion
2025-08-27
Completion
2025-08-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Candin Other / unclassified 0.5 ml Other

Indications